WTAP Expression Predicts Poor Prognosis in Malignant Glioma Patients

Xi, Zhuo; Xue, Yixue; Zheng, Jian; Liu, Xiaobai; Ma, Jun; Liu, Yunhui

doi:10.1007/s12031-016-0788-6

Cited by 74 publications

(78 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High METTL3 levels were significantly associated with poor prognosis in patients with HCC [24]. Similar to METTL3, WTAP overexpression is linked to a poor prognosis in malignant glioma patients [116]. The expression of the reader YTHDF1 also indicates a poor prognosis in patients with HCC [117].…”

Section: M6a As a Potential Biomarker And Therapeutic Targetmentioning

confidence: 93%

The interplay between m6A RNA methylation and noncoding RNA in cancer

et al. 2019

View full text Add to dashboard Cite

N6-methyladenosine (m6A) methylation, one of the most common RNA modifications, has been reported to execute important functions that affect normal life activities and diseases. Most studies have suggested that m6A modification can affect the complexity of cancer progression by regulating biological functions related to cancer. M6A modification of noncoding RNAs regulates the cleavage, transport, stability, and degradation of noncoding RNAs themselves. It also regulates cell proliferation and metastasis, stem cell differentiation, and homeostasis in cancer by affecting the biological function of cells. Interestingly, noncoding RNAs also play significant roles in regulating these m6A modifications. Additionally, it is becoming increasingly clear that m6A and noncoding RNAs potentially contribute to the clinical application of cancer treatment. In this review, we summarize the effect of the interactions between m6A modifications and noncoding RNAs on the biological functions involved in cancer progression. In particular, we discuss the role of m6A and noncoding RNAs as possible potential biomarkers and therapeutic targets in the treatment of cancers.

show abstract

Section: M6a As a Potential Biomarker And Therapeutic Targetmentioning

confidence: 93%

The interplay between m6A RNA methylation and noncoding RNA in cancer

et al. 2019

View full text Add to dashboard Cite

show abstract

“…As early as in 2016, the Liu's group published a paper showing that WTAP expression predicts poor prognosis in malignant glioma patients [46]. As WTAP is a crucial interactor of the methyltransferase complex, this and other observational works [47] suggested that m 6 A inducing enzymes, and, as a consequence, m 6 A RNA methylation, may play an oncogenic role in glioma.…”

Section: Reports About Increased M 6 a Rna Methylation In Glioblastomamentioning

confidence: 94%

Insights into the Regulatory Role of m6A Epitranscriptome in Glioblastoma

Galardi

Michienzi

Ciafrè

2020

IJMS

View full text Add to dashboard Cite

N6-methyladenosine (m6A) is one of the most widespread and abundant internal messenger RNA modifications found in eukaryotes. Emerging evidence suggests that this modification is strongly linked to the activation and inhibition of cancer pathways and is associated with prognostically significant tumour subtypes. The present review describes the dynamic nature of m6A regulator enzymes, as methyltransferases, demethylases and m6A binding proteins, and points out thevalue of the balance among these proteins in regulating gene expression, cell metabolism and cancer development. The main focus of this review is on the roles of m6A modification in glioblastoma, the most aggressive and invariably lethal brain tumour. Although the study of m6A in glioblastoma is a young one, and papers in this field can yield divergent conclusions, the results collected so far clearly demonstrate that modulation of mRNA m6A levels impacts multiple aspects of this tumour, including growth, glioma stem cells self-renewal, and tumorigenesis, suggesting that mRNA m6A modification may serve as a promising target for glioblastoma therapy. We also present recent data about another type of epitranscriptomic modification, the methylation of cytosine at a specific site of 28S rRNA, as it was recently shown to affect the biology of glioma cells, with high potential of clinical implications.

show abstract

“…WTAP is also an important part of the m 6 A methyltransferase complex. It is also highly expressed in glioma, closely correlated with pathological grade and negatively correlated with postoperative survival in glioma patients [61,62]. WTAP stimulates tumorigecity, migration and invasion of GBM cells possibly through enhancing the activity of epidermal growth factor receptor (EGFR), an important oncogenic factors in GBM [61].…”

Section: Rna M 6 a Writers In Gbmmentioning

confidence: 99%

The Emerging Roles of RNA Modifications in Glioblastoma

Dong

Cui

2020

Cancers

103

View full text Add to dashboard Cite

Glioblastoma (GBM) is a grade IV glioma that is the most malignant brain tumor type. Currently, there are no effective and sufficient therapeutic strategies for its treatment because its pathological mechanism is not fully characterized. With the fast development of the Next Generation Sequencing (NGS) technology, more than 170 kinds of covalent ribonucleic acid (RNA) modifications are found to be extensively present in almost all living organisms and all kinds of RNAs, including ribosomal RNAs (rRNAs), transfer RNAs (tRNAs) and messenger RNAs (mRNAs). RNA modifications are also emerging as important modulators in the regulation of biological processes and pathological progression, and study of the epi-transcriptome has been a new area for researchers to explore their connections with the initiation and progression of cancers. Recently, RNA modifications, especially m6A, and their RNA-modifying proteins (RMPs) such as methyltransferase like 3 (METTL3) and α-ketoglutarate-dependent dioxygenase alkB homolog 5 (ALKBH5), have also emerged as important epigenetic mechanisms for the aggressiveness and malignancy of GBM, especially the pluripotency of glioma stem-like cells (GSCs). Although the current study is just the tip of an iceberg, these new evidences will provide new insights for possible GBM treatments. In this review, we summarize the recent studies about RNA modifications, such as N6-methyladenosine (m6A), N6,2′O-dimethyladenosine (m6Am), 5-methylcytosine (m5C), N1-methyladenosine (m1A), inosine (I) and pseudouridine (ψ) as well as the corresponding RMPs including the writers, erasers and readers that participate in the tumorigenesis and development of GBM, so as to provide some clues for GBM treatment.

show abstract

WTAP Expression Predicts Poor Prognosis in Malignant Glioma Patients

Cited by 74 publications

References 21 publications

The interplay between m6A RNA methylation and noncoding RNA in cancer

The interplay between m6A RNA methylation and noncoding RNA in cancer

Insights into the Regulatory Role of m6A Epitranscriptome in Glioblastoma

The Emerging Roles of RNA Modifications in Glioblastoma

Contact Info

Product

Resources

About